What Should a Clinician Know to be Prepared for the Advent of Treatment of Retinal Dystrophies?

  1. Gregory Bock Organizer,
  2. Gerry Chader Organizer and
  3. Jamie Goode
  1. Alan C. Bird

Published Online: 7 OCT 2008

DOI: 10.1002/0470092645.ch7

Retinal Dystrophies: Functional Genomics to Gene Therapy: Novartis Foundation Symposium 255

Retinal Dystrophies: Functional Genomics to Gene Therapy: Novartis Foundation Symposium 255

How to Cite

Bird, A. C. (2003) What Should a Clinician Know to be Prepared for the Advent of Treatment of Retinal Dystrophies?, in Retinal Dystrophies: Functional Genomics to Gene Therapy: Novartis Foundation Symposium 255 (eds G. Bock, G. Chader and J. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470092645.ch7

Author Information

  1. Department of Clinical Ophthalmology, Moorfields Eye Hospital, City Road, London EC1V 2PD, UK

Publication History

  1. Published Online: 7 OCT 2008
  2. Published Print: 9 DEC 2003

Book Series:

  1. Novartis Foundation Symposia

Book Series Editors:

  1. Novartis Foundation

ISBN Information

Print ISBN: 9780470853573

Online ISBN: 9780470092644

SEARCH

Summary

It is now evident that several forms of therapy have influenced inherited retinal degeneration in animals. These are gene therapy, cell transplantation, slowing of cell death using growth factors and pharmacological approaches. There are firm proposals to initiate gene therapy in the foreseeable future. For therapy to be successful a variety of attributes of disease must be established so that the full benefits of research can be realised in clinical practice. These can be considered as identification of the causative genes, knowledge of the disease mechanisms and detection of the therapeutic effect.